
Does Medicare Cover Trulicity?
Medicare Part D plans and some Part C plans may cover Trulicity (dulaglutide) for diabetes, but the exact coverage depends on the plan. Such plans will only cover this drug for weight loss in certain cases if you're living with obesity.
Trulicity (dulaglutide) is a drug belonging to the glucagon-like peptide-1 receptor agonist (GLP-1) class of medications.
Diabetes affects 38.4 million people in the United States, or 11.6% of the population. The Food and Drug Administration (FDA) has approved this drug to help manage type 2 diabetes and reduce the chance of developing heart disease.
For this reason, although GLP-1s may be prescribed off-label for weight loss, Medicare Part D plans may cover this drug for diabetes management but not for weight loss, except under specific circumstances.
Is Trulicity covered by Medicare Part B?
Medicare is generally divided into the following parts:
Original Medicare (parts A and B)
Medicare Part D
Medicare Part C (Medicare Advantage)
Medigap
Part B
Part B mainly covers medications that you cannot administer yourself, such as IV infusions, for example. While Trulicity is an injection drug, it is one that you can inject yourself. For this reason, Medicare Part D would be responsible for covering a drug like Trulicity.
Part D
Since private insurers manage Part D plans, the exact drugs that each plan covers vary. What drugs a specific plan covers depends on its formulary, which is a list of the covered drugs.
Part D plans are generally required to cover at least two drugs from the most commonly prescribed categories. If the plan does not cover Trulicity (dulaglutide), it is likely to cover some brand-name or generic alternative.
Medicare's plan finder tool allows you to enter medications you take to see which Part D plans in your area include these medications in their formulary. The tool also lets you compare prices at different pharmacies in your area.
Part C
Medicare Part C, also called Medicare Advantage, is another option for healthcare coverage under Medicare. These optional, private plans offer the same benefits as Original Medicare. Some Part C plans may also offer other benefits, such as prescription drug coverage.
Coverage for specific medications under a Medicare Advantage plan depends on the options and plans that the company you choose offers. When selecting a Medicare Advantage plan, you can specify medications you take to compare coverage and pricing.
Why doesn't Medicare cover Trulicity for weight loss?
Medicare drug plans typically cover medications when they are considered medically necessary. Therefore, Part D plans or Part C plans with drug coverage won't cover GLP-1 agonists like Trulicity for weight loss. Typically, coverage focuses on FDA-approved uses such as helping manage type 2 diabetes or lowering cardiovascular risks for overweight adults or those living with obesity.
Obesity is defined as having a body mass index (BMI) of 30 or greater. This means you could have a BMI between 25 and 30, but would not qualify for a drug like Trulicity through Medicare unless you need it for diabetes.
Under the Biden administration, the Centers for Medicare & Medicaid Services (CMS) looked into expanding coverage of GLP-1 drugs for weight loss by 2026. However, the Trump administration has since decided against this expansion.
How much does Trulicity cost on Medicare?
Trulicity's list price is $987.19 per month, but insurance or Medicare coverage may lower this cost.
When a Medicare drug plan covers a drug, how much you'll pay out of pocket depends on the tier your plan classifies the drug within its formulary. Generally, higher-tier drugs cost more.
Copays for this medication will vary based on the plan you choose, but the manufacturer suggests a range of $0 to $100 per month after you've met your Medicare Part D deductible. Generic drugs are generally classified in a lower tier, but no generic Trulicity is currently available.
How can I lower the cost of Trulicity?
Trulicity's manufacturer offers a savings card through which you can get a one-month supply of Trulicity for as little as $25. However, you won't be able to use your Medicare plan if you want this discount.
Alternatively, you can check whether you qualify for Extra Help, which can lower your prescription costs to $4 to $9.
Other resources for lowering drug costs include:
Other tips that may help lower your prescription drug costs include:
Ask your doctor about less expensive generic options.
Consider switching from a 30-day supply to a 90-day supply for your medications, as buying a larger supply upfront can provide cost savings.
Consider a mail-order supplier to save on costs.
What is a cheaper alternative to Trulicity?
The following chart shows GLP-1 agonists currently available in the United States and their brand-name retail prices before insurance. Available generic versions usually cost less.
Brand name
(generic name) List price as of 2025
Wegovy
(semaglutide) $1,349.02
Ozempic
(semaglutide) $997.58
Rybelsus
(semaglutide $997.58
Mounjaro
(tirzepatide) $1,079.77
Zepbound
(tirzepatide) $1,086.37
Saxenda
(liraglutide) $1,349.02
Victoza
(liraglutide) $543.51 or $815.27
(depending on dose)
Trulicity
(dulaglutide) $987.19
In addition, other diabetes medications can be covered by Medicare. CMS included several of these drugs in the list of 10 drugs it used to renegotiate prices as part of the Inflation Reduction Act of 2022.
Takeaway
Trulicity is a long-lasting brand-name medication that can be quite effective at lowering high blood sugar levels due to type 2 diabetes. It is not a substitute for insulin or diet and lifestyle strategies for managing diabetes.
There is no generic version of this medication. It is typically a tier 3 medication in most drug plan formulary lists.
Many Medicare Part D plans include Trulicity on formularies, but you'll likely still pay a share of the costs. The cost you'll pay will depend on your specific plan.
A variety of private and public programs offer extra help in covering your medication costs. You can also talk with your doctor about an affordable way to manage diabetes.
The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
FDA commissioner: Measles killing about one in 1,000 victims
(NewsNation) — Health officials in the U.S. are telling all travelers that regardless of where you're flying to, it's important to make sure you're vaccinated against measles. The Centers for Disease Control and Prevention updated its guidance last week. The health agency previously advised travelers of the importance of vaccination for travelers going to countries that have had an outbreak of the disease. Lead, arsenic found in popular rice brands: Study FDA Commissioner Dr. Marty Makary told NewsNation that measles has a mortality rate of about one in 1,000 people, and usually found in people with co-morbid conditions. But he added that vaccination is effective, and that those who've had the disease before needn't worry. 'It's basically natural immunity once you've recovered from measles,' Makary said. The travel notice advises two vaccination doses for all Americans ages 1 and older. An early dose is advised for traveling infants ages 6 months to 11 months. The U.S. has seen more than 1,000 measles cases so far this year. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
38 minutes ago
- Yahoo
FDA commissioner Marty Makary to review safety of abortion drug mifepristone
June 4 (UPI) -- Food and Drug Administration Commissioner Marty Makary said he plans to review the safety of abortion drug mifepristone after a recent study raised concerns about medical side effects. In a letter to Sen. Josh Hawley, R-Mo., Makary revealed the FDA's plan on Monday to review the abortion pill after Hawley alerted the commissioner to the study. "As the Commissioner of Food and Drugs, I am committed to conducting a review of mifepristone and working with the professional career scientists at the agency who review this data," Makary wrote. "As with all drugs, FDA continues to closely monitor the postmarketing safety data on mifepristone for the medical termination of early pregnancy," Makary added. Hawley referred the FDA commissioner to the recent study, from the Ethics and Public Policy Center, which found 11% of women experienced sepsis, infection or hemorrhaging within 45 days of taking the pill. While Hawley said that information is listed as a side effect for mifepristone, the numbers are 22 times greater than the label warns. The study was based on insurance claims for 865,727 mifepristone abortions between 2017 and 2023. "I'm calling on the FDA to reinstate safety regulations on the chemical abortion drug immediately. New data out today show a massive number of severe medical side effects," Hawley said in April. "The time to act is now." Makary told senators during his confirmation hearing in March that he would oversee a review of mifepristone, but did not order it until Hawley alerted him to the EPPC study. The FDA commissioner did express concerns earlier this year about the Biden administration's policy, which allowed women to access abortion drugs without making in-person appointments. Last year, the U.S. Supreme Court rejected a challenge to the FDA's approval of mifepristone, saying the pro-life doctors who brought the case lacked standing. The court said the Alliance for Hippocratic Medicine failed to prove they suffered any harm from the FDA's policies. President Donald Trump, who supported the Supreme Court's decision, was also urged by Hawley to order a mifepristone review over the EPPC's findings.


CBS News
38 minutes ago
- CBS News
Long Beach and Inland Empire Job Corps centers close
A longtime federal program that provides job training, housing and second chances to hundreds of at-risk youth nationwide is shutting its doors in Long Beach and the Inland Empire today. "I'm kind of nervous going back out there," 20-year-old Jacob Moan said after visiting the Inland Empire Job Corps Center. "I got permission to go back with my family in Los Angeles. The thing is my whole family is gang-related except me, and I didn't want to deal with that." Moan is one of the hundreds of Job Corps students left in limbo. He has until Thursday to find another place to live. "I'll be in a motel for about two weeks until a bed opens up at the shelter," he said. "I don't know where I'm gonna go. It sucks." Dominik Rodriguez just graduated from the certified medical assistant program, but now wonders how he'll actually land a job and get money for his son. "Society just like gave up for people in my situation," he said. "It hurts." Last Thursday, the U.S. Department of Labor announced it would suspend operations at its 99 Job Corps centers due to budget constraints. The federally funded centers provide housing, job training and careers for students 16 to 24 years old. "Job Corps was created to help young adults build a pathway to a better life through education, training, and community," Secretary Lori Chavez-Deremer stated. "However, a startling number of serious incident reports and our in-depth fiscal analysis reveal the program is no longer achieving the intended outcomes that students deserve." According to the Job Corps transparency report from 2023, the program had an average of 38.6%. The total number of serious incident reports at centers was 14,913. On average, one student costs the federal government more than $80,000 a year. "The transparency report that was released was generated by someone from DOGE, who doesn't know the program, who used statistics from 2023, which were statistics that were coming out of the pandemic," said Luis Ramirez, director of the Long Beach center. "We had just over 30% enrollment at the time." Ramirez added that the center went from helping 257 students to 37, all of whom have no place to go. "They're asking if they can come home and the situations are not possible for these students and parents," Ramirez said. "The students that did leave, we're hearing they are reaching out to community services and are struggling." Ramirez is one of the 140 staff members who will be laid off in Long Beach. "When you walk through our center, we're changing lives every day," Ramirez said.